---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009382"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T11:18:57.717861+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics FY2022 net loss narrows to $43.5M; EB-101 BLA submission on track

## Summary
- Net loss $43.5M ($5.53/share) vs $84.9M ($21.57/share) in FY2021 as expense reductions offset lower revenue.
- Cash of $52.5M at Dec 31, 2022 ($50.9M at Dec 31, 2021); expected to fund operations into Q3 2024.
- Plans to submit BLA for EB-101 (RDEB) to FDA in late Q2/early Q3 2023, based on positive Phase 3 VIITAL results.
- Appointed Dmitriy Grachev as CMO; Madhav Vasanthavada as VP Business Development; Amanda Moore promoted to VP.
- Completed $35M private placement in November 2022 with institutional investors.

## SEC filing metadata
- accession: 0001493152-23-009382
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/0001493152-23-009382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009382
- JSON: https://secwatch.observer/filing/0001493152-23-009382.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009382.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported full year 2022 results: revenue $1.4 million, net income $5.53 loss per common share.
  - Period: full year 2022
  - Revenue: $1.4 million
  - Net income: $5.53 loss per common share
  - Result: reported results
  source text: License and other revenues for the year ended December 31, 2022 were $1.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/0001493152-23-009382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.